Table 3.
Proposed T-cell-dependent targets of biological therapeutics
| Target | Mechanism of action | Drug |
|---|---|---|
| IL-4 | Neutralization of IL-4 | Pascolizumab |
| IL-4R/IL-13R | Antagonism of IL‑4/IL-13 receptor | Dupilumab, Pitakinra |
| IL-5 | Neutralization of IL-5 | Mepolizumab |
| IL-6 | Neutralization of IL-6 | Sirukumab |
| IL-6R | Antagonism of IL‑6 receptor | Tocilizumab |
| IL-12, IL-23 | Inhibition of Th1 and Th17 differentiation through p40 inhibition | Ustekinumab |
| IL-17A | Neutralization of IL-17A | Secukinumab Ixekizumab |
| IL-21 | Neutralization of IL-21 | NNC0114-0006 |
| IL-22 | Neutralization of IL-22 | Fezakinumab |
| TGF-β | Neutralization of TGF-β | Fresolimumab |
| TGF-βR | Antagonism of TGF-β receptor | Galunisertib |